

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5323670

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ROMAIN OLLIER	04/12/2018
SAMUEL HOU	04/12/2018
RAMI LISSILAA	04/11/2018
DARKO SKEGRO	04/10/2018
JONATHAN BACK	04/17/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	GLENMARK PHARMACEUTICALS S.A.
<b>Street Address:</b>	CHEMIN DE LA COMBETA 5
<b>City:</b>	LA CHAUX-DE-FONDS
<b>State/Country:</b>	SWITZERLAND
<b>Postal Code:</b>	2300
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16159231
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)371-2540
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(202) 371-2600
<b>Email:</b>	eheenan@sternekessler.com, dcolonna@sternekessler.com
<b>Correspondent Name:</b>	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C
<b>Address Line 1:</b>	1100 NEW YORK AVENUE, N.W.
<b>Address Line 4:</b>	WASHINGTON, D.C. 20005
<b>ATTORNEY DOCKET NUMBER:</b>	3305.0240003/TJS/E-H/BMB
<b>NAME OF SUBMITTER:</b>	ERIN J. HEENAN #70,012
<b>SIGNATURE:</b>	/Erin J. Heenan/
<b>DATE SIGNED:</b>	01/14/2019
<b>Total Attachments: 12</b>	
source=3305_0240003_Assignment#page1.tif	

source=3305\_0240003\_Assignment#page2.tif  
source=3305\_0240003\_Assignment#page3.tif  
source=3305\_0240003\_Assignment#page4.tif  
source=3305\_0240003\_Assignment#page5.tif  
source=3305\_0240003\_Assignment#page6.tif  
source=3305\_0240003\_Assignment#page7.tif  
source=3305\_0240003\_Assignment#page8.tif  
source=3305\_0240003\_Assignment#page9.tif  
source=3305\_0240003\_Assignment#page10.tif  
source=3305\_0240003\_Assignment#page11.tif  
source=3305\_0240003\_Assignment#page12.tif

## ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Romain OLLIER, Samuel HOU, Rami LISSILAA, Darko SKEGRO and Jonathan BACK** hereby sell and assign to **GLENMARK PHARMACEUTICALS S.A.**, a corporation formed under the laws of Switzerland, whose mailing address is Chemin de la Combeta 5, 2300 La Chaux-de-Fonds, Switzerland (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **CD3/CD38 T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS AND METHODS OF THEIR PRODUCTION** for which application(s) for patent in the United States of America has United States Application No. 15/524,485, which is a U.S. National Phase of International Application No. PCT/EP2015/075628, having an international filing date of November 3, 2015, in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate

assignments in connection with such application(s) as the Assignee may deem necessary or expedient.


The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: 12.06.18 Signature of Inventor:   
Romain OLLIER

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Samuel HOU


Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Rami LISSILAA

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Darko SKEGRO

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Jonathan BACK

SIGNED on behalf of the said ASSIGNEE,

GLENMARK PHARMACEUTICALS S.A.

By:   
Name: DEAN THOMAS  
Title: Director IP  
Date: 07/05/18

9166373\_1.docx

## ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Romain OLLIER, Samuel HOU, Rami LISSILAA, Darko SKEGRO and Jonathan BACK** hereby sell and assign to **GLENMARK PHARMACEUTICALS S.A.**, a corporation formed under the laws of Switzerland, whose mailing address is Chemin de la Combeta 5, 2300 La Chaux-de-Fonds, Switzerland (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **CD3/CD38 T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS AND METHODS OF THEIR PRODUCTION** for which application(s) for patent in the United States of America has United States Application No. 15/524,485, which is a U.S. National Phase of International Application No. PCT/EP2015/075628, having an international filing date of November 3, 2015, in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate

assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.


The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.


IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Romain OLLIER

Date: 12 APR 2018 Signature of Inventor:   
Samuel HOU


Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Rami LISSILAA

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Darko SKEGRO

Date: 17 APRIL 2018 Signature of Inventor:   
Jonathan BACK

SIGNED on behalf of the said ASSIGNEE,

GLENMARK PHARMACEUTICALS S.A.

By:   
Name: DEAN THOMAS  
Title: Director IP  
Date: 07/05/18

9166373\_1.docx



## ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Romain OLLIER, Samuel HOU, Rami LISSILAA, Darko SKEGRO and Jonathan BACK** hereby sell and assign to **GLENMARK PHARMACEUTICALS S.A.**, a corporation formed under the laws of Switzerland, whose mailing address is Chemin de la Combeta 5, 2300 La Chaux-de-Fonds, Switzerland (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **CD3/CD38 T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS AND METHODS OF THEIR PRODUCTION** for which application(s) for patent in the United States of America has United States Application No. 15/524,485, which is a U.S. National Phase of International Application No. PCT/EP2015/075628, having an international filing date of November 3, 2015, in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate

assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.


The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Romain OLLIER

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Samuel HOU


Date: April 11<sup>th</sup> 2018 Signature of Inventor:   
Rami LISSILAA

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Darko SKEGRO

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Jonathan BACK

SIGNED on behalf of the said ASSIGNEE,

GLENMARK PHARMACEUTICALS S.A.

By: 

Name: DEAN THOMAS

Title: Director IP

Date: 07/05/18

<

9166373\_1.docx

## ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Romain OLLIER, Samuel HOU, Rami LISSILAA, Darko SKEGRO and Jonathan BACK** hereby sell and assign to **GLENMARK PHARMACEUTICALS S.A.**, a corporation formed under the laws of Switzerland, whose mailing address is Chemin de la Combeta 5, 2300 La Chaux-de-Fonds, Switzerland (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **CD3/CD38 T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS AND METHODS OF THEIR PRODUCTION** for which application(s) for patent in the United States of America has United States Application No. 15/524,485, which is a U.S. National Phase of International Application No. PCT/EP2015/075628, having an international filing date of November 3, 2015, in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate

assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.


The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Romain OLLIER

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Samuel HOU


Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Rami LISSILAA

Date: 10.04.2018 Signature of Inventor:   
Darko SKEGRO

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Jonathan BACK

SIGNED on behalf of the said ASSIGNEE,

GLENMARK PHARMACEUTICALS S.A.

By:   
Name: DEAN THOMAS  
Title: Director IP  
Date: 07/05/18

9166373\_1.docx